Cornell University

Maxtor Corporation

Western Digital Technologies, Inc.

Other

Seagate Technology Incorporated

Tri-institutional Therapeutics Discovery Institute

Gang Herbert Lin

Carl F Nathan

Tao Lin

Erhard Theodor Schreck

Toshihiro Imaeda

Chunjer Chuck Cheng

Tzu-Tshin Wong

Kenjiro Sato

Rei Okamoto

Michael Andrew Foley

Kazuyoshi Aso

Pradeep K Singh

Wenhu Zhan

Trevor Morgan

Laura Kirkman

Ryoma Hara

Moris Musa Dovek

Thao Anh Nguyen

Bruce C Schardt

Xiaokun L Chew

Takafumi Yukawa

Akinori Toita

Steven B Marshall

Chih-Wu Jen

Aihao Ding

Robert McKenzie

Jack Tsai

Xiaojing Ma

Masanori Kawasaki

John D Ginn

Lei Shi

Yan Wu

Don Brunnett

Duc H Banh

Robert E Eaton

Curtis W Egan

Jingbo Yu

Kezhao Zhang

John Vicars

Suet Teo

Nick Warner

Robert L Kimball

Kurt Rusnak

Hyunsil Han

Amir Ali Companieh

Rob Milby

Ron Carroll

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I′): where the substituents R, R, R, R, R, R, R', R″, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R', R″, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Macrocyclic compounds as proteasome inhibitors

The compounds of the present invention are represented by the following compounds having Formula I: where the substituents R, R, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): where the substituents R-R, R, R, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

Dipeptidomimetics as inhibitors of human immunoproteasomes

The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R-R, X, Y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

Dipeptides as inhibitors of human immunoproteasomes

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R, R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R, R, R, R, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R, R, R, R, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Peptidomimetic proteasome inhibitors

The compounds of the present invention are represented by the following compounds having Formula (I): 

Proteasome inhibitors and uses thereof

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R, RR, R&#x2032;, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R, R, R, R, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues. 

The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R, R-R, k, m, n, and q are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders, infectious disease, or for providing immunosuppression for transplanted organs or tissues. 

According to one embodiment, a head stack assembly cartridge is provided. The head stack assembly cartridge includes a base plate having a pivot shaft for pivotally mounting a head stack assembly and a base voice coil motor magnet attached to an inner surface of the base plate. The base voice coil motor magnet is arranged on the inner surface of the base plate to be adjacent to a coil of the head stack assembly pivotally mounted on the pivot shaft. The head stack assembly cartridge further includes a cover removably attached to the base plate and a pivot clamp removably attached to the cover and configured to secure the head stack assembly pivotally mounted on the pivot shaft.

Method for test mounting a head stack assembly cartridge

A hard drive component test system is provided. The hard drive component test system includes a rack having multiple test bays with first test sub-assemblies mounted in respective ones of the of test bays. A test control system is electrically coupled to each of the first test sub-assemblies. Each of the test bays is configured to receive a second test sub-assembly and to engage the second test sub-assembly with the first test sub-assembly mounted in the respective bay to form a drive assembly. The test control system is configured to selectively execute a test process on the drive assemblies mounted in the rack.

Disk drive component test system

A disk spindle assembly cartridge is described. The disk spindle assembly cartridge includes a base, a spindle motor attached to the base, a disk seated on the spindle motor, a disk clamp attached to the spindle motor, wherein the disk clamp secures the disk to the spindle motor, and a cover attached to the base. The base is configured to detachably mount a head stack assembly cartridge, where the disk is accessible to a head stack assembly pivotally mounted in the head stack assembly cartridge via an opening defined by the base and the cover.

Disk spindle assembly cartridge

According to one aspect of the present disclosure, a head stack assembly cartridge is provided. The head stack assembly cartridge includes a base plate having a pivot shaft for pivotally mounting a head stack assembly and a base voice coil motor magnet attached to an inner surface of the base plate. The base voice coil motor magnet is arranged on the inner surface of the base plate to be adjacent to a coil of the head stack assembly pivotally mounted on the pivot shaft. The head stack assembly cartridge further includes a cover removably attached to the base plate and a pivot clamp removably attached to the cover and configured to secure the head stack assembly pivotally mounted on the pivot shaft.

Head stack assembly cartridge

Growing community of inventors

San Jose, CA, United States of America

Gang Herbert Lin